fda safety communication semaglutide naion 2025 just got FDA-approved for kidney disease. This changes everything. January 2025. The approved semaglutide (Ozempic/Wegovy) for a new indication: reducing kidney disease progression in type 2 diabetes with CKD. This Ozempic® NAION Lawsuit | Attorneys

Up to 10 sessions of cognitive behavioral therapy (CBT) focusing on motivation and craving strategies as well as relapse prevention were available to every participant over the 26 weeks

According to the filing on the ClinicalTrials.gov website, the study has an estimated start of 28 April 2023 and an estimated primary completion date of March 2025

New England Journal of Medicine , 380 (4), 347-357

Both have shown efficacy in lowering HbA1c levels and supporting weight loss

The study highlights that people who used the drug had not only a 15% lower risk of heart disease but also a 23% reduction in deaths from other causes, including COVID-19